TPD52L2 and nonpapillary renal cell carcinoma: Consequently, future endeavors should focus on the following areas: Firstly, gathering extensive clinical tissue samples from ccRCC patients across multiple centers, including blood, urine, cancerous, and adjacent non-cancerous samples, to assess the expression level of TPD52L2.